Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?
Coronary artery plaque rupture results in platelet adhesion and activation, the release of adenosine diphosphate (ADP), thromboxane A(2), and the generation of thrombin. These factors propagate further platelet activation through a positive feedback mechanism, resulting in the formation of a platelet plug. The treatment of patients with ACS is centered upon the prompt initiation of both antiplatelet and anticoagulant agents. The widespread use of antiplatelet and anticoagulant agents has resulted in a significant reduction in morbidity and mortality but has also increased the risk for bleeding complications. Female gender, advanced age, low body mass index (BMI), low creatinine clearance, and the use of percutaneous coronary intervention have been consistently shown to be risk factors for bleeding. While bleeding was thought to be a necessary side effect and of little clinical significance in the past, it is now clear that bleeding is an independent predictor of adverse ischemic events and mortality. The mechanisms underlying this relationship are not yet fully elucidated and are likely multifactorial (direct effects of bleeding, increased incidence of blood transfusions, less use of antiplatelet agents in both the short and long term). Current treatment guidelines for the use of antithrombotic therapy recommend utilization of evidence-based therapies using clinical strategies shown to minimize the risk of bleeding should when possible. Novel therapies that minimize bleeding risk while providing protection against thrombotic events are needed and may improve outcomes among patients with ACS. Multiple platelet activation pathways and the coagulation cascade regulate hemostasis and thrombosis. Current antiplatelet and anticoagulant therapies for acute coronary syndromes (ACS) act on distinct sites in the pathways for platelet activation and coagulation. While these therapies are effective in reducing the morbidity and mortality associated with ACS, they are associated with a clinically significant increase in the risk of bleeding events. Novel therapies that minimize bleeding risk while providing protection against thrombotic events may improve outcomes in patients with ACS.
Cavender
Matthew A
MA
Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk J3-6, Cleveland, OH 44195, USA. matt.cavender@gmail.com
Rao
Sunil V
SV
D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced* / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
N Engl J Med. 2006 Apr 6;354(14):1464-76
16537663
Eur Heart J. 2007 May;28(10):1193-204
17456480
Am J Cardiol. 2007 Nov 1;100(9):1364-9
17950791
Circulation. 2008 Nov 18;118(21):2139-45
18981304
Circulation. 2006 Aug 22;114(8):774-82
16908769
Expert Opin Pharmacother. 2008 Aug;9(11):1869-83
18627326
J Am Coll Cardiol. 2009 Dec 1;54(23):2205-41
19942100
Lancet. 2009 Mar 14;373(9667):919-28
19286091
Lancet. 2000 Dec 16;356(9247):2037-44
11145489
Eur Heart J. 2009 Mar;30(6):655-61
18713759
Circulation. 2004 Aug 3;110(5):588-636
15289388
Circulation. 2009 Apr 14;119(14):1873-82
19332461
Am J Cardiol. 2005 Nov 1;96(9):1200-6
16253582
N Engl J Med. 1998 Aug 13;339(7):436-43
9705684
Am J Cardiol. 2003 Oct 15;92(8):930-5
14556868
J Am Coll Cardiol. 2006 May 16;47(10):2130-9
16697342
J Thromb Haemost. 2005 Aug;3(8):1800-14
16102047
Lancet. 1988 Aug 13;2(8607):349-60
2899772
Lancet. 2002 May 18;359(9319):1715-20
12049858
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s33-8
18174449
Circulation. 2004 Sep 7;110(10):1202-8
15313956
J Am Coll Cardiol. 2006 Jun 20;47(12):2374-9
16781361
N Engl J Med. 2007 Nov 15;357(20):2078-81
17982183
Pharmacol Rev. 2006 Sep;58(3):281-341
16968944
JAMA. 2004 Jul 7;292(1):45-54
15238590
Chest. 2003 Sep;124(3 Suppl):4S-10S
12970118
Circulation. 2003 Oct 7;108(14):1682-7
14504182
Arch Intern Med. 2007 Jul 23;167(14):1539-44
17646609
N Engl J Med. 2008 May 22;358(21):2218-30
18499566
Circulation. 2003 Jun 17;107(23):2884-8
12796128
Am Heart J. 2006 Mar;151(3):689.e1-689.e10
16504633
N Engl J Med. 2006 Nov 23;355(21):2203-16
17124018
J Am Coll Cardiol. 2005 Oct 18;46(8):1490-5
16226173
Eur Heart J. 2003 Oct;24(20):1815-23
14563340
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182
BMJ. 2002 Jan 12;324(7329):71-86
11786451
J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e157
17692738
Eur Heart J. 2006 May;27(9):1038-47
16476694
JAMA. 2005 Dec 28;294(24):3108-16
16380591
J Am Coll Cardiol. 2003 Feb 5;41(3):386-93
12575964
BMJ. 2000 Nov 11;321(7270):1183-7
11073508